Holen Sie sich die Stockscreener-App
28.32
2.58%
-0.75
Schlusskurs vom Vortag:
$29.07
Offen:
$29.98
24-Stunden-Volumen:
2.53M
Relative Volume:
2.59
Marktkapitalisierung:
$1.68B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.11M
KGV:
-13.02
EPS:
-2.1745
Netto-Cashflow:
$-102.47M
1W Leistung:
+10.75%
1M Leistung:
-20.58%
6M Leistung:
+23.18%
1J Leistung:
+198.11%
1-Tages-Spanne:
$27.98
$30.09
1-Wochen-Bereich:
$25.01
$30.09
52-Wochen-Spanne:
$8.98
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Firmenname
Tyra Biosciences Inc
Sektor
Branche
Telefon
(619) 728-4760
Adresse
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
28.32 | 1.68B | 0 | -131.11M | -102.47M | -2.1745 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Guggenheim | Buy |
| 2026-04-06 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Eingeleitet | William Blair | Outperform |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-10-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-08-15 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-30 | Eingeleitet | Wedbush | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2021-10-11 | Eingeleitet | BofA Securities | Buy |
| 2021-10-11 | Eingeleitet | Cowen | Outperform |
| 2021-10-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Tyra Biosciences Inc Aktie (TYRA) Neueste Nachrichten
Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tyra Biosciences Inc (TYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tyra Biosciences Inc (TYRA) Institutional Confidence - TradingKey
Tyra Biosciences Inc (TYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tyra Biosciences Inc (TYRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tyra Biosciences Inc (TYRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
TYRA PE Ratio & Valuation, Is TYRA Overvalued - Intellectia AI
TYRA Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TYRA Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Stage, Stock Gains 5.55%Earnings Seasonality - newsline.com
Tyra Biosciences (TYRA) Surges 5.55% on Strong Volume, Testing Key Resistance LevelsCash Flow Strong Stocks - newsline.com
Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism? - Yahoo Finance
Urothelial Carcinoma Market on Track for Major Expansion - openPR.com
Urothelial Carcinoma Market on Track for Major Expansion by 2036, According to DelveInsight | Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Infinity - Barchart.com
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - Moomoo
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says - Moomoo
TYRA Maintains Rating by B of A Securities -- Price Target Raised to $42 - GuruFocus
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.8, Implies 96% Upside - TradingView
BofA Securities Raises Price Target on Devon Energy to $42 From $37, Buy Rating Kept - marketscreener.com
BofA raises Tyra Biosciences stock price target on safety outlook By Investing.com - Investing.com Nigeria
Analyst Initiates Buy on Tyra Biosciences, Citing De-Risked Dabogratinib Program and Attractive Entry Ahead of Key Bladder Cancer Data - TipRanks
BofA raises Tyra Biosciences stock price target on safety outlook - Investing.com
TYRA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Tyra Biosciences (TYRA) Declines 1.67% as Stock Tests Key Support LevelsCovered Call Trade - newsline.com
Raymond James reiterates Strong Buy on Tyra Biosciences stock amid recent weakness - Investing.com Canada
TYRA: Dabogratinib advances in three FGFR3-driven indications, with pivotal data readouts ahead - TradingView
Tyra Biosciences (TYRA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Tyra Biosciences Shareholders Reelect Directors and Ratify Auditor - TipRanks
Tyra Biosciences (NASDAQ: TYRA) details 2026 shareholder meeting voting outcomes - Stock Titan
Tyra Biosciences (TYRA) director option grant tied to RA Capital funds - Stock Titan
Tyra Biosciences (TYRA) director awarded 13,160 stock options at $32.68 strike - Stock Titan
Tyra Biosciences (TYRA) director granted 13,160 stock options at $32.68 - Stock Titan
Tyra Biosciences (TYRA) director option grant held for RA Capital funds - Stock Titan
Tyra Biosciences (NASDAQ: TYRA) grants 13,160 stock options to director Adele Gulfo - Stock Titan
Director at Tyra Biosciences (NASDAQ: TYRA) awarded stock options - Stock Titan
Tyra Biosciences (TYRA) director granted 13,160 stock options - Stock Titan
[144] Tyra Biosciences, Inc. SEC Filing - Stock Titan
Tyra Biosciences Expands Precision Oncology Clinical Pipeline - asatunews.co.id
Tyra Biosciences Reports Net Loss and Advances Cancer Drug Strategy - HarianBasis.co
Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA) - Yahoo Finance
TYRA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - newsline.com
Tyra Biosciences (TYRA) Gains 2.23% as Speculative Interest Returns to BiotechKAMA Signal - The Legal Advocate
What's Driving Tyra Biosciences' Recent Surge - Kavout
Tyra Biosciences (TYRA) Advances 2.23% as Stock Closes Near Resistance at $35.08Up Down Ratio - newsline.com
Tyra Biosciences Inc. (TYRA) Faces Modest Decline as Shares Test Key Support ZoneVolume Profile - The Legal Advocate
Tyra Biosciences Inc. (TYRA) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Pipeline Progress ContinuesEarnings Quality Analysis - newsline.com
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
How Tyra Biosciences Inc. (TYRA) Affects Rotational Strategy Timing - Stock Traders Daily
This Tyra Biosciences Insider Reduced Their Stake By 58% - Moomoo
Finanzdaten der Tyra Biosciences Inc-Aktie (TYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):